Physician profile
William D Bone
NPI 1043288285
$39,063.07
in general payments reported to CMS, 2019-2025
17 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $2,064 · 2021: $6,339 · 2022: $864 · 2023: $673 · 2024: $544 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32,545.59 | 2019-2025 | |
| Allergan, INC. | $3,939.41 | 2019 | |
| Viiv Healthcare Company | $1,072.75 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $417.64 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $230.13 | 2019-2025 | Arikayce |
| Theratechnologies INC. | $168.31 | 2019-2025 | Egrifta, Trogarzo |
| Csl Behring | $130.64 | 2023-2024 | Hizentra |
| Paratek Pharmaceuticals, INC. | $119.48 | 2022 | |
| Melinta Therapeutics, LLC | $96.53 | 2019-2022 | |
| Abbvie INC. | $81.60 | 2019-2023 | Teflaro, Dalvance |
| Mayne Pharma Commercial LLC | $68.73 | 2021-2022 | |
| Octapharma USA, INC. | $51.27 | 2022-2023 | Cutaquig |
| Pfizer INC. | $40.42 | 2020-2023 | |
| Nabriva Therapeutics, Plc | $38.52 | 2021-2022 | |
| Janssen Biotech, INC. | $26.94 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $17.81 | 2021 | |
| Aimmune Therapeutics, INC. | $17.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.